Caprico Biotechnologies, Inc. (CBI) products

EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP also inhibits the transcriptional activation of NFB induced by CD40 or phorbol 12-myristate 13-acetate (PMA). Recently this protein was also proven to be the first 5’- tyrosyl-DNA phosphodiesterase. EAPII has been demonstrated to have promiscuous protein associations, broad responsiveness to various extracellular signals, and pleiotropic functions in the development of human diseases including cancer and neurodegenerative disease.

The clone 528, a mouse monoclonal antibody, specifically reacts with an epitope of the ~170 kDa extracellular protein domain of human epidermal growth factor receptor or commonly known as EGFR. Physiologically EGFR is expressed in the skin, gastrointestinal system, kidney, and other normal tissues as well as aberrantly over expresses in epithelial cancer cells of lung, pancreas, colon, breast, and on the head and neck squamous cell.

Predictive or prognostic factor in metastatic breast cancer.

Clone APN1464 recognizes cell surface CD13 antigen, a 150kDa membrane glycoprotein. The CD13 antigen is highly expressed mostly on myeloid-derived hematopoietic cells including granulocytes, monocytes, mast cells, and GM-progenitor cells. CD13 abundantly expresses on most of the malignant cells of myeloid origin such as AML, CML and also on smaller subset of cancer cells of lymphoid origin. Normal lymphocytes, platelets and erythrocytes do not express CD13. CD13 plays important role in metabolism of biologically active peptides, in phagocytosis, and in bactericidal/tumoricidal immune process. It also serves as a receptor for human coronaviruses (HCV).

The L243 reacts with human HLA-DR antigen which is expressed on B lymphocytes, monocytes, macrophages, activated T lymphocytes, activated natural killer (NK) lymphocytes, and human progenitor cells. HLA-DR is also present on thymic epithelium, B lymphocyte dependent areas of spleen and lymph node, and B cell lymphomas.

Clone CF-1D12 recognizes human CD52, a 21-28 kDa glycoprotein whose C-terminus is glycophosphatidylinositol (GPI) anchored within the membrane. It is also known as Cambridge pathology antigen 1 (CAMPATH-1). Binding of CF-1D12 with CD52 induces a potent complement-mediated cytolytic immune response of matured lymphocytes. It is widely expressed on the surface of thymocytes and mature lymphocytes, on monocytes, dendritic cells, eosinophils and epithelial cells of the epididymis and seminal vesicles but not on neutrophils, plasma cells, platelets or erythrocytes.